Their drug was approved in the 1st qtr and earned a $50M milestone payment from Takeda Pharmacueticals. Here is a link to their income statement. http://finance.yahoo.com/q/is?s=AFFYNotice the big jump in revenue from the previous quarters.
Now here is a link to their balance sheet. http://finance.yahoo.com/q/bs?s=AFFY Notice how the receivables jumped from $7.3M to $59.4M. This was the $50M milestone receivable being booked.
There you go...is this enough proof for Queen Sauve9?
Excellent ! Thanks. Having spent many years licensing patents & products to Japanese companies am excited for Arena. Successful Licensing of products to Japanese companies can be a slow process involving numerous and highly detailed discussions. Arena is to be commended. Any idea if Eisai has the opportunity to earn back some of the up-front money over time if certain sales goals are met ?